$245 Million is the total value of Tamarack Advisers, LP's 21 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTIequity | $29,402,000 | +11.2% | 3,050,000 | +56.4% | 11.99% | +58.8% |
| MDT | Buy | MEDTRONIC PLCequity | $25,014,000 | -2.2% | 275,000 | +5.8% | 10.20% | +39.7% |
| NUVA | Sell | NUVASIVE INCequity | $24,780,000 | -33.8% | 500,000 | -4.8% | 10.10% | -5.4% |
| Buy | NOVOCURE LTDequity | $22,432,000 | -32.9% | 670,000 | +5.5% | 9.15% | -4.1% | |
| ATRC | Buy | ATRICURE INCequity | $18,360,000 | +90.6% | 600,000 | +118.2% | 7.49% | +172.3% |
| NXTM | Buy | NXSTAGE MEDICAL INCequity | $17,888,000 | +6.9% | 625,000 | +4.2% | 7.29% | +52.7% |
| SRCL | Buy | STERICYCLE INCequity | $15,593,000 | -28.2% | 425,000 | +14.9% | 6.36% | +2.6% |
| LNTH | Buy | LANTHEUS HOLDINGS INCequity | $15,259,000 | +5.2% | 975,000 | +0.5% | 6.22% | +50.3% |
| BIO | Sell | BIO-RAD LABORATORIES-Aequity | $13,933,000 | -31.5% | 60,000 | -7.7% | 5.68% | -2.2% |
| RIGL | Buy | RIGEL PHARMACEUTICALS INCequity | $12,650,000 | -13.4% | 5,500,000 | +20.9% | 5.16% | +23.7% |
| SCI | Buy | SERVICE CORP INTERNATIONALequity | $11,072,000 | +17.1% | 275,000 | +28.6% | 4.52% | +67.3% |
| HOLX | Sell | HOLOGIC INCequity | $8,220,000 | -42.7% | 200,000 | -42.9% | 3.35% | -18.1% |
| PTLA | New | PORTOLA PHARMACEUTICALS INCequity | $7,808,000 | – | 400,000 | +100.0% | 3.18% | – |
| MCK | New | MCKESSON CORPequity | $5,524,000 | – | 50,000 | +100.0% | 2.25% | – |
| CORV | Buy | CORREVIO PHARMA CORPequity | $5,291,000 | -36.1% | 2,125,000 | +3.2% | 2.16% | -8.7% |
| OBLN | OBALON THERAPEUTICS INCequity | $4,347,000 | -23.3% | 2,100,000 | 0.0% | 1.77% | +9.5% | |
| VSI | VITAMIN SHOPPE INCequity | $2,844,000 | -52.6% | 600,000 | 0.0% | 1.16% | -32.3% | |
| OPTN | Sell | OPTINOSE INCequity | $1,860,000 | -82.6% | 300,000 | -65.1% | 0.76% | -75.2% |
| STRM | Buy | STREAMLINE HEALTH SOLUTIONSequity | $1,580,000 | -29.5% | 1,950,000 | +2.6% | 0.64% | +0.6% |
| OPHT | OPHTHOTECH CORPequity | $1,200,000 | -49.2% | 1,000,000 | 0.0% | 0.49% | -27.4% | |
| New | PTLA US 03/15/19 C30call | $175,000 | – | 3,500 | +100.0% | 0.07% | – | |
| Exit | MDCO US 10/19/18 P25put | $0 | – | -2,000 | -100.0% | -0.02% | – | |
| Exit | AMGN US 01/18/19 P210put | $0 | – | -200 | -100.0% | -0.06% | – | |
| Exit | SPY US 10/19/18 P290put | $0 | – | -1,500 | -100.0% | -0.08% | – | |
| Exit | GILD US 01/18/19 C85call | $0 | – | -2,500 | -100.0% | -0.10% | – | |
| Exit | IWM US 10/19/18 P165put | $0 | – | -7,000 | -100.0% | -0.15% | – | |
| Exit | ALKS US 12/21/18 C45call | $0 | – | -2,000 | -100.0% | -0.20% | – | |
| MODN | Exit | MODEL N INCequity | $0 | – | -100,000 | -100.0% | -0.45% | – |
| GKOS | Exit | GLAUKOS CORPequity | $0 | – | -75,000 | -100.0% | -1.39% | – |
| PCRX | Exit | PACIRA PHARMACEUTICALS INCequity | $0 | – | -150,000 | -100.0% | -2.10% | – |
| GILD | Exit | GILEAD SCIENCES INCequity | $0 | – | -175,000 | -100.0% | -3.86% | – |
| CORI | Exit | CORIUM INTERNATIONAL INCequity | $0 | – | -1,425,000 | -100.0% | -3.87% | – |
| LH | Exit | LABORATORY CRP OF AMER HLDGSequity | $0 | – | -160,000 | -100.0% | -7.94% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.